RxDoctor Payments Data

Roberto Gonzalez, MD

Internal Medicine · El Paso, TXNPI 1891159349

Payments from drug & device makers

$3,245in general payments, 2019–2025

Across 128 payments — averaging $25.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$704
  • AstraZeneca$596
  • Novo Nordisk$555
  • Lilly USA, LLC$314
  • Abbott$228
  • Radius Health, Inc.$166
  • plus $681 from 11 others

What the payments were for

  • Food & beverage$3,21699%
  • Education$291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,245 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$35,786
Medicare patients
92
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide236$339,265
MounjaroTirzepatide239$327,831
FarxigaDapagliflozin Propanediol158$229,654
EnbrelEtanercept24$219,726
JardianceEmpagliflozin95$154,865
TrulicityDulaglutide74$139,534
RybelsusSemaglutide56$118,553
TymlosAbaloparatide33$117,186
JanumetSitagliptin Phos/Metformin Hcl81$105,535
JanuviaSitagliptin Phosphate68$100,140
EliquisApixaban66$87,795
ProliaDenosumab43$75,268
InvokanaCanagliflozin35$58,781
VascepaIcosapent Ethyl52$41,225
Janumet XrSitagliptin Phos/Metformin Hcl32$40,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$314$467,365313 claims
Novo NordiskOzempic, Rybelsus$555$457,819292 claims
AmgenEnbrel, Prolia$704$294,99467 claims
MerckJanumet, Januvia, Janumet Xr$103$246,006181 claims
AstraZenecaFarxiga, Breztri Aerosphere$596$241,454173 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$76$195,909129 claims
Radius Health, Inc.Tymlos$166$117,18633 claims
PfizerEliquis$27$87,79566 claims
Johnson & JohnsonInvokana, Xarelto$108$82,69548 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →